Clinical trials: Cognition - Other
Schizophrenia, Cognition
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of…
- Conditions
- Schizophrenia, Cognition, Psychosis
- Trial name
- NCT02104752
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Haemophilia A, Haemophilia B
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents.
- Trial name
- eTHINK (NCT03660774)
- Testing
- No treatment given
- Where
- 22 sites in United States
- Volunteers
- 563 people
- Sponsor
- Novo Nordisk A/S
Schizophrenia; Psychosis, Cognitive Impairment
Hjernegym - Effects of Exergaming in Psychosis: a Clinical Intervention Study
The goal of this clinical intervention study is to investigate the effects of exergaming on cognition and other clinical symptoms in outpatient individuals with schizophrenia.
- Trial name
- NCT05858255
- Testing
- Exergaming
- Where
- Norway
- Volunteers
- 48 people
- Sponsor
- Sykehuset i Vestfold HF
Schizophrenia, Psychosis
Social Cognitive Training for Psychosis: Treatment Development
The primary aim of this proposal is to develop, refine, manualize and assess the feasibility and preliminary efficacy of a brief, narrowly-focused social cognitive intervention for individuals with psychosis.
- Trial name
- NCT01579422
- Testing
- social cognitive training
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Yale University
Schizophrenia
Magnetic Seizure Therapy for Schizophrenia
This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety among schizophrenia patients.
- Trial name
- NCT02746965
- Testing
- Magpro X100 + Option, ThymatronSystem Ⅳ Electroconvulsive System, treatment as usual (TAU)
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Cognitive Dysfunction
Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia
This study examined whether adding structured supportive psychotherapy to risperidone treatment is more effective than risperidone alone in improving cognitive function and reducing inflammation in patients with schizophrenia.
- Conditions
- Schizophrenia, Cognitive Dysfunction, Inflamation
- Trial name
- SUPPORT-SCZ (NCT07477301)
- Testing
- Structured Supportive Psychotherapy, Risperidone 2 mg
- Where
- Indonesia
- Volunteers
- 46 people
- Sponsor
- Hasanuddin University
Schizophrenia
Effect on Cognitive Function of a Treatment With Aripiprazole
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
- Trial name
- NCT00329810
- Testing
- Aripiprazole
- Volunteers
- 500 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophenia Disorder, Schizoaffective Disorder
Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills
STUDY PURPOSE: To study whether patients who have schizophrenia or schizoaffective disorder and are randomly assigned to switch to aripiprazole prior to participation in a brief vocational skills training (VST) will have improved…
- Trial name
- NCT00223418
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
Pharmacological Approach to Improve the Outcome of Social Cognition Training
This study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of Social Cognitive Skills Training (SCST).
- Trial name
- NCT01517360
- Testing
- Oxytocin, Social Cognitive Skills Training
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Psychotic Disorder, Cognitive Function 1, Social
Social Cognition and Interaction Training for Adults With Psychotic Disorders: An Open Pilot Study in Finland
33 individuals with a psychotic disorder were given 22-24 sessions weekly or twice weekly of Social Cognition and Interaction Training (SCIT) and evaluated at the baseline and after the intervention.
- Trial name
- NCT02399020
- Testing
- Social Cognition and Interaction Training
- Where
- Finland
- Volunteers
- 33 people
- Sponsor
- Helsinki University Central Hospital
Schizophrenia
A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia
The study is a double-blind, placebo-controlled, random-order, single-dose crossover trial of sildenafil 50 \& 100 mg added to stable antipsychotic treatment in schizophrenia patients to assess whether this PDE5 inhibitor…
- Trial name
- NCT00455715
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
The purpose of this study is to test a new computerized training program as well as to find out whether the computer training might help people who have schizophrenia.
- Trial name
- TARA (NCT01773239)
- Testing
- TARA computer-based exercises
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Posit Science Corporation
Schizophrenia
Effects of Galantamine on Cognition
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties, with cognitive impairments and negative symptoms frequently emerging much earlier.
- Trial name
- NCT01100775
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Memory Disorders
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit…
- Conditions
- Schizophrenia, Memory Disorders, Cognition Disorders
- Trial name
- Atomoxetine (NCT00548327)
- Testing
- Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Borderline Personality Disorder, BPD
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
Social cognition impairment is critical to the pathology and morbidity of a number of psychiatric disorders, including the schizophrenia spectrum, the autism spectrum and the personality disorders, thus representing a dimension…
- Conditions
- Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD
- Trial name
- NCT02149823
- Testing
- Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU)
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Maria de las Mercedes Perez Rodriguez
Mood Disorders, Schizophrenia
Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness
The aim of this study is to assess the efficacy of a short term compensatory cognitive group intervention - the Compensatory Cognitive Training (CCT) among people with severe mental illnesses, receiving ambulatory treatment
- Conditions
- Mood Disorders, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT04551027
- Testing
- compensatory cognitive treatment
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Shalvata Mental Health Center
Schizophrenia
A Study of a Remediation Program of Social Cognition in Schizophrenia
Theory of mind (ability to infer others' intention, emotion, etc) is known to be altered in patients with schizophrenia and its deficit to be correlated with their decreased social proficiency.
- Trial name
- REMEDCOG (NCT01077791)
- Testing
- original cognitive therapy
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.
- Trial name
- NCT00176423
- Testing
- galantamine
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Effects of Buspirone Combined With Clozapine
This study aimed to evaluate the enhancing effects of different doses of buspirone on psychiatric symptoms and cognitive function in patients with schizophrenia.
- Trial name
- NCT06906224
- Testing
- Low-dose group (buspirone tablets, clozapine), High-dose group (buspirone tablets, clozapine)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Chuanfu Song
Schizophrenia
The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory
Deficits in working memory (WM) performance are the most significant cognitive impairments in schizophrenia (SCZ). It has also been shown that WM performance is contingent on the cortex synchronization, a process that relies on…
- Trial name
- NCT01494623
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health